INCY vs NTRA
Incyte vs Natera, Inc. — AI-powered side-by-side comparison
| Metric | INCY | NTRA |
|---|
| AI Score |
72
|
65
|
| Price |
$121.08
|
$312.59
|
| P/E Ratio |
14.89×
|
-229.94×
|
| ROE |
24.9%
|
-12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
65.3%
|
| Debt / Equity |
0.01×
|
0.12×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
71.1
|
| Beta |
0.769
|
1.514
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus NTRA.
INCY leads by 7 points.
INCY scores 72/100 (Buy) versus NTRA at 65/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- RSI at 71 is in overbought territory — Technical